CN105796498A - 一种粉末包衣叶酸及其制备方法 - Google Patents
一种粉末包衣叶酸及其制备方法 Download PDFInfo
- Publication number
- CN105796498A CN105796498A CN201410844331.3A CN201410844331A CN105796498A CN 105796498 A CN105796498 A CN 105796498A CN 201410844331 A CN201410844331 A CN 201410844331A CN 105796498 A CN105796498 A CN 105796498A
- Authority
- CN
- China
- Prior art keywords
- folic acid
- coating
- powder coating
- preparation
- coating material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 332
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 171
- 239000011724 folic acid Substances 0.000 title claims abstract description 171
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 163
- 229960000304 folic acid Drugs 0.000 title claims abstract description 163
- 239000000843 powder Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 238000000576 coating method Methods 0.000 claims abstract description 120
- 239000011248 coating agent Substances 0.000 claims abstract description 118
- 239000000463 material Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000005516 engineering process Methods 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000036541 health Effects 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 230000032683 aging Effects 0.000 claims description 27
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 13
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000004408 titanium dioxide Substances 0.000 claims description 10
- 239000001069 triethyl citrate Substances 0.000 claims description 10
- 235000013769 triethyl citrate Nutrition 0.000 claims description 10
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 10
- 206010044565 Tremor Diseases 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 230000006641 stabilisation Effects 0.000 claims description 9
- 238000011105 stabilization Methods 0.000 claims description 9
- 229960003943 hypromellose Drugs 0.000 claims description 8
- 239000003605 opacifier Substances 0.000 claims description 7
- 239000004014 plasticizer Substances 0.000 claims description 7
- 239000003086 colorant Substances 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- -1 antiplastering aid Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 abstract description 10
- 238000004090 dissolution Methods 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 7
- 238000012545 processing Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 239000012467 final product Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 37
- 238000009472 formulation Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 14
- JOAQINSXLLMRCV-UHFFFAOYSA-N 4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}benzoic acid Chemical compound C1=NC2=NC(N)=NC(O)=C2N=C1CNC1=CC=C(C(O)=O)C=C1 JOAQINSXLLMRCV-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 11
- 239000012535 impurity Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000008240 homogeneous mixture Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 229940014144 folate Drugs 0.000 description 6
- 238000007922 dissolution test Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001016 megaloblastic anemia Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410844331.3A CN105796498B (zh) | 2014-12-30 | 2014-12-30 | 一种粉末包衣叶酸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410844331.3A CN105796498B (zh) | 2014-12-30 | 2014-12-30 | 一种粉末包衣叶酸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105796498A true CN105796498A (zh) | 2016-07-27 |
CN105796498B CN105796498B (zh) | 2019-02-19 |
Family
ID=56420031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410844331.3A Active CN105796498B (zh) | 2014-12-30 | 2014-12-30 | 一种粉末包衣叶酸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105796498B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107913275A (zh) * | 2017-11-06 | 2018-04-17 | 广州市桐晖药业有限公司 | 一种叶酸的保存方法 |
CN114983954A (zh) * | 2022-06-15 | 2022-09-02 | 广州新济药业科技有限公司 | 叶酸片及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030049314A1 (en) * | 2001-08-28 | 2003-03-13 | Liang Matthew H. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
CN101401809A (zh) * | 2008-11-12 | 2009-04-08 | 杭州民生药业集团有限公司 | 一种维生素和矿物质组合物的制备工艺 |
CN103070831A (zh) * | 2013-02-02 | 2013-05-01 | 常州市新鸿医药化工技术有限公司 | 10~90%叶酸颗粒制备方法 |
-
2014
- 2014-12-30 CN CN201410844331.3A patent/CN105796498B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030049314A1 (en) * | 2001-08-28 | 2003-03-13 | Liang Matthew H. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
CN101401809A (zh) * | 2008-11-12 | 2009-04-08 | 杭州民生药业集团有限公司 | 一种维生素和矿物质组合物的制备工艺 |
CN103070831A (zh) * | 2013-02-02 | 2013-05-01 | 常州市新鸿医药化工技术有限公司 | 10~90%叶酸颗粒制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107913275A (zh) * | 2017-11-06 | 2018-04-17 | 广州市桐晖药业有限公司 | 一种叶酸的保存方法 |
CN114983954A (zh) * | 2022-06-15 | 2022-09-02 | 广州新济药业科技有限公司 | 叶酸片及其制备方法 |
CN114983954B (zh) * | 2022-06-15 | 2023-09-12 | 广州新济药业科技有限公司 | 叶酸片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105796498B (zh) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105456270A (zh) | 一种二肽基肽酶ⅳ抑制剂药物组合物、其用途及其制备方法 | |
EP2612659B1 (en) | Panaxatriol saponins enteric pellet, capsule comprising same and method for preparing same | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN102846575B (zh) | 硝苯地平缓释片及其制备方法 | |
CN103435496B (zh) | 一种盐酸溴己新化合物,其制备方法及其药物组合物和制剂 | |
CN107595782A (zh) | 一种利奈唑胺干混悬剂及其制备方法 | |
CN105796498A (zh) | 一种粉末包衣叶酸及其制备方法 | |
CN105496941B (zh) | 一种叶酸固体制剂及其制备方法 | |
CN106278907B (zh) | 一种盐酸曲恩汀化合物 | |
CN104622854A (zh) | 含有盐酸氨溴索和硫酸沙丁胺醇的片剂 | |
CN106361712A (zh) | 一种格列美脲片剂及其制备方法 | |
CN105769872B (zh) | 一种快速溶出的枸橼酸莫沙必利组合物 | |
CN104415034B (zh) | 一种咪达那新药物组合物及其制备方法 | |
CN104188914B (zh) | 复方阿莫西林粉及其生产工艺 | |
CN104324013B (zh) | 吲达帕胺缓释剂的制备工艺 | |
CN103159710B (zh) | 用于抗病毒的十氢萘衍生物 | |
CN105520913B (zh) | 一种包含沙格列汀的微丸、其用途及其制备方法 | |
CN104415340A (zh) | 一种固体药物制剂及其制备方法 | |
CN106913537A (zh) | 一种醋酸阿比特龙舌下片剂及其制备方法 | |
CN104138365B (zh) | 一种替米沙坦胶囊剂及其制备方法 | |
CN104337783B (zh) | 一种卡培他滨片剂及其制备方法 | |
CN106310286B (zh) | 一种甲苯磺酸妥舒沙星组合物 | |
CN105796515A (zh) | 一种依帕列净口崩片及其制备方法 | |
CN104706606A (zh) | 一种枸橼酸西地那非片剂及其制备方法 | |
CN104644601B (zh) | 一种卡培他滨片剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Powder coated folic acid and preparation method thereof Effective date of registration: 20200122 Granted publication date: 20190219 Pledgee: Beijing Yizhuang International Financing Guarantee Co.,Ltd. Pledgor: BEIJING SILIAN PHARMACEUTICAL INDUSTRY Co.,Ltd. Registration number: Y2020990000097 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210818 Granted publication date: 20190219 Pledgee: Beijing Yizhuang International Financing Guarantee Co.,Ltd. Pledgor: BEIJING SILIAN PHARMACEUTICAL INDUSTRY Co.,Ltd. Registration number: Y2020990000097 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a powder coated folic acid and a preparation method thereof Effective date of registration: 20210818 Granted publication date: 20190219 Pledgee: Beijing Yizhuang International Financing Guarantee Co.,Ltd. Pledgor: BEIJING SILIAN PHARMACEUTICAL INDUSTRY Co.,Ltd. Registration number: Y2021990000732 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230330 Granted publication date: 20190219 Pledgee: Beijing Yizhuang International Financing Guarantee Co.,Ltd. Pledgor: BEIJING SILIAN PHARMACEUTICAL INDUSTRY Co.,Ltd. Registration number: Y2021990000732 |